Ticker LaunchIPO · VERV
Verve Therapeutics, Inc.
Verve Therapeutics, Inc. (VERV) priced its initial public offering on Jun 17, 2021 at $19.00 per share, above its $16.00–$18.00 range, raising $266.7M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $876.1M. J.P. Morgan was lead-left underwriter, joined by Jefferies, Guggenheim and William Blair. WilmerHale advised the company and Cooley advised the underwriters.
- Status
- IPO
- Ticker
- VERV
- Exchange
- Nasdaq Global Select
- Priced
- Jun 17, 2021
- IPO price
- $19.00
- Price range
- $16.00–$18.00
- Raised
- $266.7M
- Market cap at IPO price
- $876.1M
- First filed
- May 28, 2021
- Underwriters
- J.P. Morgan, Jefferies, Guggenheim and William Blair
- Company counsel
- WilmerHale
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed May 28, 2021
- Latest amendment Jun 14, 2021
- Final prospectus (424B4) Jun 17, 2021
- All filings on EDGAR CIK 1840574
Other Biotech & pharma IPOs in 2021
- iSpecimen Inc.ISPC · Jun 21, 2021 · $18M
- Atai Beckley N.V.ATAI · Jun 21, 2021 · $225M
- Ambrx Biopharma Cayman, Inc.AMAM · Jun 21, 2021 · $126M
- Century Therapeutics, Inc.IPSC · Jun 21, 2021 · $211M
- Molecular Partners AGMOLN · Jun 16, 2021 · $63.8M
- Alzamend Neuro, Inc.ALZN · Jun 15, 2021 · $12.5M
The free weekly recap
Every Monday: the IPOs that priced and filed, SPAC deals and closings, and what is expected to price this week, from the filings.